Petrovax Pharm secures award at Man and Medicine congress

Petrovax Pharm, a Russian biopharmaceutical company, secures a win in the Socially Responsible Business nomination at the "Man and Medicine" Russian National Congress. The prize is awarded for outstanding achievements in the medical and pharmaceutical industries, which contribute to the promotion of health and improvement of the quality of life of the society.

The award ceremony was held as a part of the annual congress that brings together leading specialists in medicine and pharmaceuticals. Aleksander Chuchalin, Academician of the Russian Academy of Science, Professor, founder and president of the congress personally delivered the prize.

Petrovax Pharm was honored with the award for its support of a project developed to raise awareness of pneumococcal infection prevention among people with chronic non-communicable diseases and those at risk. Petrovax Pharm considers these efforts to be its major focus.

Pneumococcus ranks third as a cause of all infectious diseases^[1]. It is responsible for up to 70 % of cases of community-acquired pneumonia requiring hospitalization^[2]. According to specialists, vaccination against pneumococcal infection contributes significantly to increasing life expectancy and reduces mortality, which is especially important for the elderly and people with various chronic diseases.

One of the key efforts supported by Petrovax Pharm was a series of meetings among the professional medical community to tackle immunization problems in the adult population, organized by the Russian Society for Prevention of Non-Communicable Diseases (RSPNCD).

Academician Aleksander Chuchalin also stressed the control measures taken to combat antimicrobial resistance^[3] in his report. According to his speech, antimicrobial resistance is one of the top global threats to public health, a direct cause of 1.27 million deaths worldwide in 2019^[4].

Resistance occurs primarily due to emerging bacterial biofilms. In severe injuries, wounds and other and infectious processes, biofilms prevent antimicrobial drugs from having any effect. Destroying these biofilms is a path to more efficient treatment.

Therefore, this issue is highly important to be dealt with. For example, according to clinical studies^[5], the original development bovhyaluronidase azoximer (Longidaza) in combination with antibacterial therapy helps to fight biofilms in various diseases including urological, gynecological and lung conditions.